Strategies facilitating the permeation of nanoparticles through blood-brain barrier: An insight towards the development of brain-targeted drug delivery system

[1]  In-Jung Lee,et al.  Magnesium and Zinc Oxide Nanoparticles from Datura alba Improve Cognitive Impairment and Blood Brain Barrier Leakage , 2022, Molecules.

[2]  J. Park,et al.  Blood-brain barrier–penetrating single CRISPR-Cas9 nanocapsules for effective and safe glioblastoma gene therapy , 2022, Science advances.

[3]  Annu,et al.  An Insight to Brain Targeting Utilizing Polymeric Nanoparticles: Effective Treatment Modalities for Neurological Disorders and Brain Tumor , 2022, Frontiers in Bioengineering and Biotechnology.

[4]  Neisseria Meningitidis Opca Protein/MnO 2 Hybrid Nanoparticles for Overcoming Blood Brain Barrier to Treat Glioblastoma , 2022, Advanced Materials.

[5]  Liang Han.  Modulation of the Blood–Brain Barrier for Drug Delivery to Brain , 2021, Pharmaceutics.

[6]  G. Murtaza,et al.  Potential of Nanocarrier-Based Drug Delivery Systems for Brain Targeting: A Current Review of Literature , 2021, International journal of nanomedicine.

[7]  C. Riccardi,et al.  Nanoparticle-Guided Brain Drug Delivery: Expanding the Therapeutic Approach to Neurodegenerative Diseases , 2021, Pharmaceutics.

[8]  Andrew J. S. Knox,et al.  Modulating the Blood–Brain Barrier: A Comprehensive Review , 2021, Pharmaceutics.

[9]  W. Burggren,et al.  Form and Function of the Vertebrate and Invertebrate Blood-Brain Barriers , 2021, International journal of molecular sciences.

[10]  A. Neves,et al.  Nanoparticles for Targeted Brain Drug Delivery: What Do We Know? , 2021, International journal of molecular sciences.

[11]  P. Kesharwani,et al.  Nanotherapeutics approaches for targeting alpha synuclien protein in the management of Parkinson disease , 2021 .

[12]  Lijuan Duan,et al.  Nanoparticle Delivery of CRISPR/Cas9 for Genome Editing , 2021, Frontiers in Genetics.

[13]  B. Baradaran,et al.  Immune Cell Membrane-Coated Biomimetic Nanoparticles for Targeted Cancer Therapy. , 2021, Small.

[14]  Jin Zhao,et al.  PMPC Modified PAMAM Dendrimer Enhances Brain Tumor-Targeted Drug Delivery. , 2021, Macromolecular bioscience.

[15]  Lixiang Wang,et al.  Development of L-carnosine functionalized iron oxide nanoparticles loaded with dexamethasone for simultaneous therapeutic potential of blood brain barrier crossing and ischemic stroke treatment , 2021, Drug delivery.

[16]  Tanmay Kulkarni,et al.  Nanomechanical Insight of Pancreatic Cancer Cell Membrane during Receptor Mediated Endocytosis of Targeted Gold Nanoparticles , 2020, ACS Applied Bio Materials.

[17]  L. Cucullo,et al.  A blood–brain barrier overview on structure, function, impairment, and biomarkers of integrity , 2020, Fluids and barriers of the CNS.

[18]  E. Shusta,et al.  Blood–Brain Barrier Modulation to Improve Glioma Drug Delivery , 2020, Pharmaceutics.

[19]  Ilya L Sokolov,et al.  Fast processes of nanoparticle blood clearance: Comprehensive study. , 2020, Journal of controlled release : official journal of the Controlled Release Society.

[20]  S. Flora,et al.  Nanotechnology: A Promising Approach for Delivery of Neuroprotective Drugs , 2020, Frontiers in Neuroscience.

[21]  Marc Schneider,et al.  Key for crossing the BBB with nanoparticles: the rational design , 2020, Beilstein journal of nanotechnology.

[22]  M. Narayan,et al.  Nanocarriers as Potential Drug Delivery Candidates for Overcoming the Blood–Brain Barrier: Challenges and Possibilities , 2020, ACS omega.

[23]  Heiko Meyer,et al.  The Septate Junction Protein Tetraspanin 2A is critical to the Structure and Function of Malpighian tubules in Drosophila melanogaster. , 2020, American journal of physiology. Cell physiology.

[24]  R. Daneman,et al.  The blood–brain barrier in health and disease: Important unanswered questions , 2020, The Journal of experimental medicine.

[25]  G. Billman.  Homeostasis: The Underappreciated and Far Too Often Ignored Central Organizing Principle of Physiology , 2020, Frontiers in Physiology.

[26]  Nathan S. Mosier,et al.  Nanoscale Drug Delivery Systems: From Medicine to Agriculture , 2020, Frontiers in Bioengineering and Biotechnology.

[27]  Benjamin J. Umlauf,et al.  Exploiting BBB disruption for the delivery of nanocarriers to the diseased CNS. , 2019, Current opinion in biotechnology.

[28]  S. Maji,et al.  α-Synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis. , 2019, Biochimica et biophysica acta. Proteins and proteomics.

[29]  R. Yoshimura,et al.  A single-nucleotide polymorphism influences brain morphology in drug-naïve patients with major depressive disorder , 2019, Neuropsychiatric disease and treatment.

[30]  David V. Schaffer,et al.  CRISPR-Cas9-Mediated Genome Editing Increases Lifespan and Improves Motor Deficits in a Huntington’s Disease Mouse Model , 2019, Molecular therapy. Nucleic acids.

[31]  D. Fairlie,et al.  Alpha-synuclein structure and Parkinson’s disease – lessons and emerging principles , 2019, Molecular Neurodegeneration.

[32]  A. Schätzlein,et al.  Nose-to-Brain Delivery , 2019, The Journal of Pharmacology and Experimental Therapeutics.

[33]  Heebeom Koo,et al.  Active Targeting Strategies Using Biological Ligands for Nanoparticle Drug Delivery Systems , 2019, Cancers.

[34]  Y. Mardor,et al.  Transient blood–brain barrier disruption is induced by low pulsed electrical fields in vitro: an analysis of permeability and trans-endothelial electric resistivity , 2019, Drug delivery.

[35]  M. Kruszewski,et al.  Toxicity of metallic nanoparticles in the central nervous system , 2019, Nanotechnology Reviews.

[36]  Z. Bian,et al.  Review of Current Strategies for Delivering Alzheimer’s Disease Drugs across the Blood-Brain Barrier , 2019, International journal of molecular sciences.

[37]  M. Scarpa,et al.  Possible strategies to cross the blood–brain barrier , 2018, Italian Journal of Pediatrics.

[38]  M. A. Motaleb,et al.  I‐131 doping of silver nanoparticles platform for tumor theranosis guided drug delivery , 2018, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[39]  V. Ghate,et al.  Application of pectin‑zinc oxide hybrid nanocomposite in the delivery of a hydrophilic drug and a study of its isotherm, kinetics and release mechanism. , 2018, International journal of biological macromolecules.

[40]  Y. Yeo,et al.  Surface modification of polymer nanoparticles with native albumin for enhancing drug delivery to solid tumors. , 2018, Biomaterials.

[41]  R. Kamm,et al.  In vitro models of molecular and nano-particle transport across the blood-brain barrier. , 2018, Biomicrofluidics.

[42]  Chenghua Gu,et al.  Bridging barriers: a comparative look at the blood–brain barrier across organisms , 2018, Genes & development.

[43]  Xiaowei Dong,et al.  Current Strategies for Brain Drug Delivery , 2018, Theranostics.

[44]  Berislav V. Zlokovic,et al.  Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders , 2018, Nature Reviews Neurology.

[45]  Roger M. Leblanc,et al.  Crossing the blood‐brain barrier with nanoparticles , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[46]  Leland S. Hu,et al.  Is the blood–brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data , 2018, Neuro-oncology.

[47]  M. Harirchian,et al.  Safety and Efficacy of Nanocurcumin as Add-On Therapy to Riluzole in Patients With Amyotrophic Lateral Sclerosis: A Pilot Randomized Clinical Trial , 2018, Neurotherapeutics.

[48]  Bruno Sarmento,et al.  Chemical modification of drug molecules as strategy to reduce interactions with mucus☆ , 2017, Advanced drug delivery reviews.

[49]  Huile Gao,et al.  Increased Gold Nanoparticle Retention in Brain Tumors by in Situ Enzyme-Induced Aggregation. , 2016, ACS nano.

[50]  V. Adam,et al.  Nanocarrier drugs in the treatment of brain tumors , 2016 .

[51]  D. B. Vieira,et al.  Getting into the brain: liposome-based strategies for effective drug delivery across the blood–brain barrier , 2016, International journal of nanomedicine.

[52]  Raquel Ferreira,et al.  Nanoparticle-mediated brain drug delivery: Overcoming blood-brain barrier to treat neurodegenerative diseases. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[53]  A. Jong,et al.  Pathogenic Triad in Bacterial Meningitis: Pathogen Invasion, NF-κB Activation, and Leukocyte Transmigration that Occur at the Blood-Brain Barrier , 2016, Front. Microbiol..

[54]  Mohammad Abdollahi,et al.  Toxicity of Nanoparticles and an Overview of Current Experimental Models , 2016, Iranian biomedical journal.

[55]  S. Carmichael,et al.  Blood-brain barrier breakdown and neovascularization processes after stroke and traumatic brain injury. , 2015, Current opinion in neurology.

[56]  Yue Zhao,et al.  Enhanced anti-ischemic stroke of ZL006 by T7-conjugated PEGylated liposomes drug delivery system , 2015, Scientific Reports.

[57]  Tiantian Zhang,et al.  Nucleic Acid Aptamers: An Emerging Tool for Biotechnology and Biomedical Sensing , 2015, Sensors.

[58]  Louise van der Weerd,et al.  Enhanced glutathione PEGylated liposomal brain delivery of an anti-amyloid single domain antibody fragment in a mouse model for Alzheimer's disease. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[59]  G. Pastorin,et al.  Blood–brain barrier transport studies, aggregation, and molecular dynamics simulation of multiwalled carbon nanotube functionalized with fluorescein isothiocyanate , 2015, International journal of nanomedicine.

[60]  D. Begley,et al.  Neuronopathic lysosomal storage disorders: Approaches to treat the central nervous system. , 2015, Best practice & research. Clinical endocrinology & metabolism.

[61]  M. Strumia,et al.  Nanoparticle-cored dendrimers: functional hybrid nanocomposites as a new platform for drug delivery systems. , 2015, Nanoscale.

[62]  C. Fong.  Permeability of the Blood–Brain Barrier: Molecular Mechanism of Transport of Drugs and Physiologically Important Compounds , 2015, The Journal of Membrane Biology.

[63]  I. Shelef,et al.  Anatomy and physiology of the blood-brain barrier. , 2015, Seminars in cell & developmental biology.

[64]  Sujan Dutta,et al.  Biocompatible mesoporous silica-coated superparamagnetic manganese ferrite nanoparticles for targeted drug delivery and MR imaging applications. , 2014, Journal of colloid and interface science.

[65]  A. Falcão,et al.  Intranasal administration of carbamazepine to mice: a direct delivery pathway for brain targeting. , 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[66]  A. Chacko,et al.  Pathways for Small Molecule Delivery to the Central Nervous System Across the Blood-Brain Barrier , 2014, Perspectives in medicinal chemistry.

[67]  P. Henrich-Noack,et al.  Surfactants, not size or zeta-potential influence blood-brain barrier passage of polymeric nanoparticles. , 2014, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[68]  T. Davis,et al.  Transporters at CNS barrier sites: obstacles or opportunities for drug delivery? , 2014, Current pharmaceutical design.

[69]  G. V. van Dongen,et al.  Pharmacokinetics, Brain Delivery, and Efficacy in Brain Tumor-Bearing Mice of Glutathione Pegylated Liposomal Doxorubicin (2B3-101) , 2014, PloS one.

[70]  B. Zlokovic,et al.  Pericyte loss influences Alzheimer-like neurodegeneration in mice , 2013, Nature Communications.

[71]  T. Sobrino,et al.  In Vivo Theranostics at the Peri-Infarct Region in Cerebral Ischemia , 2013, Theranostics.

[72]  Peter C. Searson,et al.  The blood-brain barrier: an engineering perspective , 2013, Front. Neuroeng..

[73]  G. Xiao,et al.  Receptor-Mediated Endocytosis and Brain Delivery of Therapeutic Biologics , 2013, International journal of cell biology.

[74]  M A Vandelli,et al.  Potential use of polymeric nanoparticles for drug delivery across the blood-brain barrier. , 2013, Current medicinal chemistry.

[75]  R. Dijkhuizen,et al.  MRI of ICAM-1 Upregulation After Stroke: the Importance of Choosing the Appropriate Target-Specific Particulate Contrast Agent , 2013, Molecular Imaging and Biology.

[76]  Xiang Yun,et al.  Nanoparticles for Targeted Delivery of Antioxidant Enzymes to the Brain after Cerebral Ischemia and Reperfusion Injury , 2013, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[77]  R. Daneman,et al.  The blood–brain barrier in health and disease , 2012, Annals of neurology.

[78]  W. Pardridge,et al.  Drug Transport across the Blood–Brain Barrier , 2012, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[79]  Svetlana Gelperina,et al.  Transport of drugs across the blood-brain barrier by nanoparticles. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[80]  Hong Yuan,et al.  Brain-targeting study of stearic acid–grafted chitosan micelle drug-delivery system , 2012, International journal of nanomedicine.

[81]  N. Oku,et al.  Amelioration of cerebral ischemia-reperfusion injury based on liposomal drug delivery system with asialo-erythropoietin. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[82]  Lihong Liu,et al.  Modern methods for delivery of drugs across the blood-brain barrier. , 2012, Advanced drug delivery reviews.

[83]  Toral Patel,et al.  Polymeric nanoparticles for drug delivery to the central nervous system. , 2012, Advanced drug delivery reviews.

[84]  Xinguo Jiang,et al.  The targeted delivery of anticancer drugs to brain glioma by PEGylated oxidized multi-walled carbon nanotubes modified with angiopep-2. , 2012, Biomaterials.

[85]  B. Zlokovic,et al.  Central nervous system pericytes in health and disease , 2011, Nature Neuroscience.

[86]  D. Frenkel,et al.  Designing super selectivity in multivalent nano-particle binding , 2011, Proceedings of the National Academy of Sciences.

[87]  Bengt R. Johansson,et al.  Pericytes regulate the blood–brain barrier , 2010, Nature.

[88]  W. Hennink,et al.  In Vivo Methods to Study Uptake of Nanoparticles into the Brain , 2010, Pharmaceutical Research.

[89]  Robert Langer,et al.  Nanotechnology in drug delivery and tissue engineering: from discovery to applications. , 2010, Nano letters.

[90]  Luis M Liz-Marzán,et al.  Recent Progress on Silica Coating of Nanoparticles and Related Nanomaterials , 2010, Advanced materials.

[91]  L. Chinn,et al.  Evolutionary Conservation of Vertebrate Blood–Brain Barrier Chemoprotective Mechanisms in Drosophila , 2009, The Journal of Neuroscience.

[92]  K. Black,et al.  PDE5 inhibitors enhance tumor permeability and efficacy of chemotherapy in a rat brain tumor model , 2008, Brain Research.

[93]  J. Scherrmann,et al.  CNS Delivery Via Adsorptive Transcytosis , 2008, The AAPS Journal.

[94]  K P Bhatia,et al.  The role of DAT-SPECT in movement disorders , 2008, Journal of Neurology, Neurosurgery & Psychiatry.

[95]  Mikko Gynther,et al.  Prodrug Approaches for CNS Delivery , 2008, The AAPS Journal.

[96]  Jean-Pierre Benoit,et al.  Active targeting of brain tumors using nanocarriers. , 2007, Biomaterials.

[97]  K. Black,et al.  Calcium-activated potassium channels mediated blood-brain tumor barrier opening in a rat metastatic brain tumor model , 2007, Molecular Cancer.

[98]  W. Pardridge.  Molecular biology of the blood-brain barrier , 2005, Methods in molecular medicine.

[99]  B. Testa,et al.  Lessons learned from marketed and investigational prodrugs. , 2004, Journal of medicinal chemistry.

[100]  D. Begley,et al.  ABC transporters and the blood-brain barrier. , 2004, Current pharmaceutical design.

[101]  A. Sidhu,et al.  Modulation of dopamine transporter function by α‐synuclein is altered by impairment of cell adhesion and by induction of oxidative stress , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[102]  B. Engelhardt.  Development of the blood-brain barrier , 2003, Cell and Tissue Research.

[103]  E. Lo,et al.  Antiactin-Targeted Immunoliposomes Ameliorate Tissue Plasminogen Activator-Induced Hemorrhage after Focal Embolic Stroke , 2003, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[104]  S. Vannucci,et al.  Glucose Transporter Asymmetries in the Bovine Blood-Brain Barrier* , 2001, The Journal of Biological Chemistry.

[105]  P. Chan,et al.  The development of a new mouse model of global ischemia: focus on the relationships between ischemia duration, anesthesia, cerebral vasculature, and neuronal injury following global ischemia in mice , 1998, Brain Research.

[106]  Daocheng Wu,et al.  Rapid and efficient crossing blood-brain barrier: Hydrophobic drug delivery system based on propionylated amylose helix nanoclusters. , 2017, Biomaterials.

[107]  D. Begley,et al.  Transcytosis of macromolecules at the blood-brain barrier. , 2014, Advances in pharmacology.

[108]  K. Hynynen,et al.  Focused ultrasound disruption of the blood-brain barrier: a new frontier for therapeutic delivery in molecular neurooncology. , 2012, Neurosurgical focus.

[109]  C. L. Ventola,et al.  The nanomedicine revolution: part 1: emerging concepts. , 2012, P & T : a peer-reviewed journal for formulary management.

[110]  B. Eliceiri,et al.  Zebrafish model of the blood-brain barrier: morphological and permeability studies. , 2011, Methods in molecular biology.

[111]  W. Pardridge.  The blood-brain barrier: Bottleneck in brain drug development , 2005, NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics.

[112]  Y. Kawashima,et al.  Brain targeting with surface-modified poly(D,L-lactic-co-glycolic acid) nanoparticles delivered via carotid artery administration. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[113]  Robert Blumenthal,et al.  Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. , 2009, Critical reviews in therapeutic drug carrier systems.